Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
RARE MULTI-SITE DENTAL PLATFORM — $1.8M ADJ. EBITDA / 29% MARGINS This great two-location dental platform dominates federally designated Dental Health Professional Shortage Areas in rural... Businesses Franchises Brokers Loading... Rare Multi-Site Dental Platform Pennsylvania Asking Price:$9,950,000 Cash Flow (SDE):$1,800,000 EBITDA:Not Disclosed Gross Revenue:$6,200,000 Established:2009 Rare Multi-Site Dental Platform Business Description 6 Producing Doctors | 29% Margins | Dominant in Underserved Markets RARE MULTI-SITE DENTAL PLATFORM — $1.8M ADJ. EBITDA / 29% MARGINS This great two-location dental platform dominates federally designated Dental Health Professional Shortage Areas in rural Pennsylvania. The Company brings a 17-year operating history, ~$6.2M revenue, ~$1.8M Adjusted EBITDA (~29% margin), 93%+ gross margins, and ~8% historical revenue CAGR. WHY THIS PLATFORM WINS - In-house sedation and operating facilities staffed by dental anesthesiologists — a capability nearly all regional competitors must refer out. Eliminates referral leakage and creates a genuine clinical moat. - Associate-supported clinical model: six producing dentists (including dedicated hospital-dentistry providers), five hygienists, and a 45-person team. Production is not dependent on any single doctor. - Dominant positioning with government-enrolled patients in markets where fewer than 1 in 4 dentists accept them. Demand structurally exceeds supply. - Diversified payer mix across commercial, government, and self-pay channels. - Recently re-engineered operating model: structural cost reductions, cloud-based systems, disciplined KPI tracking. The margin expansion is already done — a buyer inherits it on day one. - Leadership with $600M+ combined revenue oversight and $780M of DSO M&A and integration experience across 300+ dental clinic operations. - Defined multi-phase expansion roadmap to replicate the model across rural Pennsylvania and adjacent Northeast states. PROCESS — BUILT FOR SPEED Every inquiry receives our Non-Disclosure Agreement for electronic execution within minutes. Executed parties receive same-day access to the full Confidential Information Memorandum and a structured Q&A channel. This is an advisor-run process with defined timelines — serious buyers will not be left waiting. All identifying details are withheld pending NDA. Financial figures reflect Adjusted EBITDA; full basis and adjustment bridge are detailed in the CIM. Ad#:2516968 Detailed Information Employees: 40 (36 Full-time, 4 Part-time) Team includes six producing dentists and five hygienists, plus seasonal and PRN Facilities: Two leased clinical facilities anchor the platform, including a ~7,900 sq. ft. primary clinic and a second full-service location in an adjacent county. The platform's proprietary in-house sedation and operating suites — staffed by dental anesthesiologists — represent infrastructure that is rare at this scale and expensive to replicate. Combined occupancy cost is approximately $20,100/month under leases with terms and renewal options extending through 2028–2030. All clinical equipment, imaging, and FF&E remain with the operating entity; cloud-based practice management systems were implemented in the recent operational transformation. Competition: The Company operates in federally designated Dental Health Professional Shortage Areas where provider supply is structurally constrained and fewer than 1 in 4 dentists accept government-enrolled patients. Its proprietary in-house sedation and operating capability has no local equivalent — competitors must refer these cases out. The result is a durable demand moat in markets with persistent unmet need. Growth & Expansion: Defined multi-phase expansion roadmap: deepen capacity utilization in existing markets, replicate the proven model in adjacent underserved Pennsylvania regions, then extend into neighboring Northeast states. Operating systems, clinical protocols, and the leadership bench were rebuilt specifically to support geographic replication — the platform is built to scale. Financing: Seller financing available To be discussed with qualified buyers; transaction structure detailed in the CIM. Support & Training: Experienced clinical and administrative leadership remains in place to support a smooth transition, and a buyer inherits a re-engineered, KPI-driven operating model rather than a turnaround project. Transition support and continuity arrangements are discussed with qualified parties under NDA. Reason for Selling: Strategic ownership transition; full details shared with qualified buyers Business Location Real Estate: Leased Lease Expiration: 01/11/2030 Rent: $13,000.00 Listing Statistics Saved This Listing Listing Last Updated Appeared in Search Listing Detail Views BizBuySell EDGE Know the True Market Value Before You Make an Offer Get valuation data to negotiate with confidence. Get a Valuation Report Business Listed By: Project Summit AMIVA Equity Partners LLC View My Listings Phone Number 973-604-3111 Voice only (no SMS) Sponsoring Broker: MIke Pantouvakis Ad#:2516968 The information in this listing has been provided by the business seller or representative stated above. BizBuySell has no stake in the sale of this business, has not independently verified any of the information about the business, and assumes no responsibility for its accuracy or completeness. Read BizBuySell's Terms of Use before responding to any ad. Learn how to avoid scams. Contact Form Full Name* Enter a valid Full Name Phone Number Enter Phone Number Email Address* Enter Email Address Optional Message Yes, send me the Buyer Newsletter for popular businesses, tips, & email promotions. Show sellers you’re serious - learn about BizBuySell Edge for premium buyer tools & alerts Send Message By clicking the button, you agree to BizBuySell’s Terms of Use and Privacy Notice Business Listed By: Project Summit AMIVA Equity Partners LLC View My Listings Phone Number 973-604-3111 Voice only (no SMS) Sponsoring Broker: MIke Pantouvakis Your request has been sent. What Happens Next? is reviewing your details. A representative will reach out soon to discuss your options. Expect a response in 1-2 business days. Report an issue with this listing Similar Listings Dental Practices for Sale Medical Practices for Sale All Businesses for Sale in Pennsylvania Top Brand In-Home Senior Care, Appraised Price Pittsburgh, PA Asking: $27,228,000 Philadephia Home Care Agency for sale with 471 clients Philadelphia County, PA Asking: $20,999,999 Home Health Care Skilled Pennsylvania Philadelphia, PA Asking: $18,000,000 WCH Service Bureau Franchise Opportunity Cash Required: $45,000 ©2026 CoStar Group Send Message Listing Shared via Email Buy a Business Search for a Business Established Businesses Asset Sales How to Buy a Business Buy a Franchise Search Franchises For Sale Low Cost Franchises Restaurant and Food Franchises Business Opportunities Retail Franchises Sell a Business Sell a Business on BizBuySell Sell Multiple Businesses How to Sell a Business Value a Business Find a Broker Tools & Advice Learning Center Finance Center Market Insights Financial Benchmarks Business for Sale Blog Business Brokers Find a Broker For Brokers My BizBuySell Dashboard My Business Selling My Listings Guide to Selling Add a New Listing Searching My Saved Listings My Saved Searches Franchise Recommendations BizBuySell Edge Edge Preferences Recommendations Industry Benchmarks Location Insights BizBuySell Edge Edge Preferences Recommendations Industry Benchmarks Location Insights Research Guide to Buying Reports Message Center My Mailbox My Inquiries Email Preferences Export Leads Account Account Settings My Billing Info BrokerWorks My BizBuySell Dashboard Leads Billing My Saved Listings My Saved Searches Account Sign Out Sign In a6301374279843840.cdn.optimizely.com a6301374279843840.cdn.optimizely.com is blocked This page has been blocked by an extension Try disabling your extensions. ERR_BLOCKED_BY_CLIENT Reload This page has been blocked by an extension reCAPTCHA Recaptcha requires verification. protected by reCAPTCHA
Why we like it
- Earnings quality is strong for a dental deal: $1.8M adjusted EBITDA on $6.2M revenue is a 29% margin with 93%+ gross margins, and production is spread across six dentists rather than one owner. That diversification lowers key-person risk, which is the single biggest reason dental buyers overpay and then get burned. The margin expansion was already executed, so a buyer inherits it rather than betting on a turnaround.
- The moat is real and hard to replicate: in-house sedation suites staffed by dental anesthesiologists let the group keep complex cases that competitors must refer out. That capability is expensive to build and rare at this scale, so it functions as both a revenue capture mechanism and a referral magnet. Combined with dominance in shortage-designated areas, the demand structurally exceeds local supply.
- The tailwind is demographic and structural rather than cyclical: these are federally designated Dental Health Professional Shortage Areas where fewer than 1 in 4 dentists accept government-enrolled patients. Dental care is non-discretionary for the underlying population, and government payer participation gives a durable volume floor. Unmet need in these markets tends to persist through any economic cycle.
- Operator advantage is baked in: the business runs on cloud-based systems, disciplined KPI tracking, and an associate-supported clinical model. A buyer with DSO or multi-site experience can plug this into an existing back office and pursue the stated roadmap into adjacent Pennsylvania and Northeast markets. The infrastructure was rebuilt specifically to support replication, not just to run two sites.
- The 5.53x cash flow multiple is reasonable for a diversified, multi-doctor dental platform with this margin profile. Seller financing is available, which signals the seller's confidence and lets a buyer improve cash-on-cash returns. Compared to single-doctor practices trading at 2.5x to 4x, the premium here reflects durability and scale, not hype.
How to improve it
- Push capacity utilization at the existing two sites before spending a dollar on new locations. The listing flags underutilized capacity as the first phase of the roadmap, so audit chair-time productivity, hygiene recall rates, and unfilled schedule slots to convert existing fixed cost into incremental margin. This is the cheapest revenue growth available.
- Add or expand high-value service lines that leverage the in-house sedation and operating suites, such as complex extractions, implants, and hospital dentistry. These are the exact cases competitors refer out, so capturing more of them raises revenue per patient and defends the moat. Track case mix and referral-in volume to quantify the upside.
- Renegotiate and renew the leases early given expirations run 2028 to 2030. Locking in favorable terms and options now removes a diligence overhang and protects the sedation-suite infrastructure that is expensive to relocate. Consider whether a future purchase of the primary 7,900 sq ft facility makes sense to control occupancy cost.
- Optimize the payer mix and fee schedules across commercial, government, and self-pay channels. Government-enrolled patients drive volume but usually carry thinner reimbursement, so layering in higher-margin commercial and self-pay cosmetic and implant work improves blended economics. Build a KPI dashboard tracking net collection rate by payer.
- Invest in doctor and hygienist recruiting and retention pipelines, because provider supply is the binding constraint in shortage areas. Locking in the six producing dentists with retention agreements and building associate onboarding capacity is what makes the replication roadmap credible. Growth here is gated by clinical staffing, not by demand.
- Formalize the expansion playbook into a repeatable acquisition and de novo model. With leadership carrying $780M of DSO M&A experience, the buyer should codify site selection criteria, integration checklists, and unit economics targets before deploying capital into adjacent markets. Disciplined replication beats opportunistic expansion.
- Implement patient acquisition and reactivation marketing to fill the demand that structurally exceeds supply. Even in underserved markets, capturing more of the unmet need requires local outreach, community health partnerships, and recall systems. Small marketing spend against a supply-constrained demand base should convert efficiently.
Diligence notes
- Scrutinize the adjusted EBITDA bridge closely. The listing repeatedly says figures reflect Adjusted EBITDA and that the full adjustment basis is in the CIM, so verify which add-backs are legitimate versus aggressive. Confirm the $1.8M is defensible after real market-rate clinical compensation for all six producing doctors.
- Verify doctor compensation and retention. Multi-doctor production is the entire thesis, so confirm each dentist's contract, comp structure, non-compete, and intent to stay post-close. If any producing doctor drives outsized production and could walk, the diversification argument weakens and the earnings are at risk.
- Examine the payer mix and reimbursement stability, especially government-enrolled patient revenue. Understand exposure to Medicaid fee schedule changes, reimbursement timing, and any single-payer concentration. Government-heavy dental economics can shift with state budget cycles, so stress-test collections.
- Confirm the leases and the sedation-suite infrastructure. With expirations spanning 2028 to 2030 and the anesthesiology capability described as expensive to replicate, verify renewal options, rent escalators, and whether the specialized suites can be maintained or moved if a landlord pushes back. Occupancy risk is understated in a leased dental platform.
- Validate the growth and CAGR claims independently. The listing cites 8% historical revenue CAGR and a completed margin transformation, so request trailing monthly financials to confirm the margin expansion is durable and not a recent one-time cut. Distinguish sustainable improvements from timing benefits.
- Clarify the actual reason for sale and ownership structure. The listing gives a vague strategic ownership transition and withholds identifying details pending NDA. Determine whether this is a private equity flip, a founder exit, or a partial recapitalization, because that reveals how much of the experienced leadership bench actually stays.
Source
Want the full analysis on every deal? Unlock the complete platform with Accredited Pro to screen live listings and read our operator-level writeups.